Why cagrilintide alone is discussed so much less than in combination

Research-use-only cagrilintide is not approved for human use and the published evidence base is a clinical-trial evidence base. Those two facts sit uncomfortably together and both are true.

Adding the measurement that post #21 says would settle it.

Cagrilintide molecular characteristics: it is a synthetic amylin analogue, substituted to prevent the amyloidogenicity of human amylin. The sequence is short and analytically straightforward to confirm by LC-MS.

The general answer and the answer for your case may diverge here.

Published human data on cagrilintide alone is thinner than on the combination, which is the reverse of what most people assume from how it is discussed here.

The interest in combining it with semaglutide is that two different satiety mechanisms might add. Whether they do, and by how much, is exactly what the combination trials were designed to find out rather than something to be assumed.

Helpful, and short, which on this subject is harder than long.

Adding the measurement that post #60 says would settle it.

The CagriSema phase 2 paper: a fixed combination of the two components in one weekly injection. The trade-off of a fixed combination is that you cannot titrate the components independently and you cannot attribute effect to one component from a combination trial.

Published human data on cagrilintide alone is thinner than on the combination, which is the reverse of what most people assume from how it is discussed here.

I would put a moderate confidence on that and no more.

On dosing intervals: the long-acting design supports weekly administration, and the escalation schedules in the published trials are gentler than the compound's potency alone would suggest. Tolerability is the constraint.